Skip to main navigation

Countdown toNOPAIN Act:

Days

ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.

Get More Details

Main navigation

About Us
- About Us
- Board of Directors
Commitment
Products
Partnerships
- Grants
- Partnerships for the Future
News
- In The News
- Archive
Investors
Sustainability
Careers

Home
Investors
In the News
Archive
Events

Archived News Releases

Keyword Search

Year

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

09/09/24

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

08/09/24

Pacira BioSciences Reports Second Quarter 2024 Financial Results

07/30/24

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

07/23/24

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

07/10/24

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

05/30/24

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

05/10/24

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

05/08/24

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

05/07/24

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

05/07/24

Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024

04/30/24

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

04/02/24

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

03/13/24

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

03/06/24

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

02/29/24

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

02/22/24

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

02/15/24

Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.

02/07/24

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

01/04/24

Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

01/03/24

Shareholder Tools

RSS Feeds
Email Alerts

Contact Us
Legal
Site Map
Privacy Notice

EXPAREL^® (bupivacaine liposome injectable suspension), iovera^o, ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), and Pacira are registered trademarks of the respective subsidiaries of Pacira BioSciences, Inc. All other trademarks referenced herein are the property of their respective owners.

©2024 Pacira Pharmaceuticals , Inc. a wholly owned Subsidiary of Pacira BioSciences, Inc.

Effective January 1, 2025

NOPAIN ACT

ASP+6% CMS reimbursement for proven non-opioids, like EXPAREL, used in all outpatient surgical settings^1-3

Get More Details on the NOPAIN Act

ASP, average sales price; CMS, Centers for Medicare and Medicaid Services; NOPAIN, Non-Opioids Prevent Addiction in the Nation.

References: 1. Congress.gov. One hundred seventeenth congress of the United States of America. Accessed June 12, 2024. https://www.congress.gov/117/bills/hr2617/BILLS-117hr2617enr.pdf 2. CMS.gov. Medicare part B drug average sales price. Updated April 2, 2024. Accessed June 13, 2024. https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price 3. EXPAREL Prescribing Information. San Diego, CA; Pacira Pharmaceuticals, Inc., November 2023.

Proceed to PACIRA